• 1
    Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 16271640.
  • 2
    De Hertogh G, Aerssens J, Geboes KP, et al. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol. 2008; 14: 845852.
  • 3
    Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427434.
  • 4
    Vermeire S, Rutgeerts P. Antibody responses in Crohn's disease. Gastroenterology. 2004; 126: 601604.
  • 5
    Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128: 20202028.
  • 6
    Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008; 103: 665681.
    Direct Link:
  • 7
    Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004; 99: 23762384.
    Direct Link:
  • 8
    Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101: 360367.
    Direct Link:
  • 9
    Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007; 56: 13941403.
  • 10
    Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004; 53: 11171122.
  • 11
    Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996; 110: 18101819.
  • 12
    Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 1998; 93: 13061310.
    Direct Link:
  • 13
    Satsangi J, Landers CJ, Welsh KI, et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4: 1826.
  • 14
    Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007; 13: 15611566.
  • 15
    Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007; 13: 20282036.
  • 16
    Joossens S, Colombel JF, Landers C, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006; 55: 16671669.
  • 17
    Dotan I, Fishman S, Dgani Y, et al. Antibodies against Laminaribioside and Chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006; 131: 366378.
  • 18
    Dotan N, Altstock RT, Schwarz M, et al. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus. 2006; 15: 442450.
  • 19
    Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009; 9: 80.
  • 20
    StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp, 2009.
  • 21
    Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007; 56: 15361542.
  • 22
    Lakatos PL, Altorjay I, Mandi Y, et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens. 2008; 71: 552559.
  • 23
    Malickova K, Lukas M, Donoval R, et al. Novel anti-carbohydrate autoantibodies in patients with inflammatory bowel disease: are they useful for clinical practice? Clin Lab. 2006; 52: 631638.
  • 24
    Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010; 16: 13671375.
  • 25
    Rieder F, Lopez R, Franke A, et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease — a longitudinal analysis. PLoS One. 2011; 6: e18172.
  • 26
    Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2010; 16: 263274.
  • 27
    Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009; 104: 14261434.
  • 28
    Koutroubakis IE, Drygiannakis D, Tsirogianni A, et al. Anti-glycan antibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2011; 56: 845852.
  • 29
    Simondi D, Mengozzi G, Betteto S, et al. Anti-glycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 645651.
  • 30
    Malickova K, Lakatos PL, Bortlik M, et al. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. Eur J Gastroenterol Hepatol. 2010; 22: 144150.
  • 31
    Rejchrt S, Drahosova M, Kopacova M, et al. Antilaminaribioside and antichitobioside antibodies in inflammatory bowel disease. Folia Microbiol (Praha). 2008; 53: 373376.
  • 32
    Dotan I. Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig Dis. 2009; 27: 206211.
  • 33
    Lakatos PL, Papp M, Rieder F. Serologic anti-glycan antibodies in inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 406412.
  • 34
    Lakatos PL, Altorjay I, Szamosi T, et al; Hungarian IBD StudyGroup. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009; 15: 365374.
  • 35
    Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008; 14: 51155124.
  • 36
    Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955962
  • 37
    Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010; 42: 11181125.
  • 38
    Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011; 43: 246252.
  • 39
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19( Suppl A): 536.
  • 40
    Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease—‘colitis indeterminate.’ J Clin Pathol. 1978; 31: 567577.